Abstract
Huntington's disease (HD) is an autosomal dominant neurological disease. It is a fatal neurological disorder affecting 5-10 out of 10,000 people. While there are intensive research efforts focusing on uncovering molecular mechanisms of the pathogenesis of HD, a number of studies have begun to look for effective therapies for HD. There is a large body of encouraging news on novel therapeutic developments. The present paper reviews drugs used for symptomatic treatment of HD and experimental therapies targeting HD molecular pathology.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Amantadine / therapeutic use
-
Animals
-
Cell Transplantation
-
Drugs, Chinese Herbal / therapeutic use
-
Humans
-
Huntingtin Protein
-
Huntington Disease / drug therapy*
-
Huntington Disease / genetics
-
Huntington Disease / therapy
-
Mutation
-
Neostriatum / cytology
-
Nerve Tissue Proteins / genetics*
-
Neuroprotective Agents / therapeutic use*
-
Nuclear Proteins / genetics*
-
Riluzole / therapeutic use
Substances
-
Drugs, Chinese Herbal
-
HTT protein, human
-
Huntingtin Protein
-
Nerve Tissue Proteins
-
Neuroprotective Agents
-
Nuclear Proteins
-
Riluzole
-
Amantadine